You-Seok Kim1,2, Qiang Li1, Hwa-Young Youn1, Dae Young Kim3. 1. Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea. 2. KPC Corporation, Oporo, Gwangju, Republic of Korea. 3. Department of Life Science, College of Bio-nano Technology, Gachon University, Seongnam, Republic of Korea davekim@gachon.ac.kr.
Abstract
BACKGROUND/AIM: Idiopathic pulmonary fibrosis (PF) is a fatal disorder of unknown aetiology with limited treatment options. Chitosan has antibacterial, antifungal, antioxidant, antitumour, and anti-inflammatory effects. This study aimed to investigate the effects of chitosan administration on bleomycin (BLM)-induced PF in rats. MATERIALS AND METHODS: A PF rat model was established by endotracheal instillation of 5 mg/kg BLM; then, chitosan was administered in drinking water for 3 weeks. Histology, cell counts, and cytokine responses in the bronchoalveolar lavage fluid (BALF) and weight measurements (body and lung) were analyzed to assess its therapeutic effects. RESULTS: Chitosan administration tended to reduce transforming growth factor (TGF)-β1 and interferon (IFN)-γ levels in BALF, and histopathological examination confirmed that chitosan attenuated the degree of inflammation and fibrosis in the lung. CONCLUSION: This study revealed that oral chitosan exhibits potential antifibrotic effects, as measured by decreased proinflammatory cytokine levels and histological evaluation, in a BLM-induced PF rat model. Copyright
BACKGROUND/AIM: Idiopathic pulmonary fibrosis (PF) is a fatal disorder of unknown aetiology with limited treatment options. Chitosan has antibacterial, antifungal, antioxidant, antitumour, and anti-inflammatory effects. This study aimed to investigate the effects of chitosan administration on bleomycin (BLM)-induced PF in rats. MATERIALS AND METHODS: A PF rat model was established by endotracheal instillation of 5 mg/kg BLM; then, chitosan was administered in drinking water for 3 weeks. Histology, cell counts, and cytokine responses in the bronchoalveolar lavage fluid (BALF) and weight measurements (body and lung) were analyzed to assess its therapeutic effects. RESULTS:Chitosan administration tended to reduce transforming growth factor (TGF)-β1 and interferon (IFN)-γ levels in BALF, and histopathological examination confirmed that chitosan attenuated the degree of inflammation and fibrosis in the lung. CONCLUSION: This study revealed that oral chitosan exhibits potential antifibrotic effects, as measured by decreased proinflammatory cytokine levels and histological evaluation, in a BLM-induced PF rat model. Copyright
Authors: W A Wuyts; S Willems; R Vos; B M Vanaudenaerde; S I De Vleeschauwer; M Rinaldi; H M Vanhooren; N Geudens; S E Verleden; M G Demedts; M Thomeer; E K Verbeken; G M Verleden Journal: Exp Lung Res Date: 2010-09-27 Impact factor: 2.459
Authors: Lívia A Tavares; Allan A Rezende; Jymmys L Santos; Charles S Estevam; Ana M O Silva; Jaderson K Schneider; John L S Cunha; Daniela Droppa-Almeida; Ivan J Correia-Neto; Juliana C Cardoso; Patricia Severino; Eliana B Souto; Ricardo L C de Albuquerque-Júnior Journal: Pharmaceutics Date: 2021-05-09 Impact factor: 6.321
Authors: Josep Mercader-Barceló; Joan Truyols-Vives; Carlos Río; Nora López-Safont; Ernest Sala-Llinàs; Alice Chaplin Journal: Int J Mol Sci Date: 2020-08-22 Impact factor: 5.923